

1 **DECLARATION OF LEON CHIU**

2 I, LEON CHIU, declare:

3 1. I am over the age of eighteen, have personal knowledge of the facts contained  
4 herein and would and could testify competently thereto if called as a witness.

5 2. I am an executive based in Torrance, California. In October, 1999, I was the Vice-  
6 President of a company called Synapse Capital, LLC. Synapse Capital controls two multi-million  
7 dollar investment funds--Synapse Fund I, LLC and Synapse Fund II, LLC.

8 3. Through my work for Synapse Capital, I was called upon to investigate a possible  
9 investment in a company called Sutura, Inc., headed by one Anthony Nobles.

10 4. As a course of normal due diligence, I hired a firm in Woodland Hills called  
11 Scherzer International ([www.scherzer.com](http://www.scherzer.com)) to uncover any past misdeeds by Anthony Nobles.  
12 Scherzer reported directly to me; overseeing such investigations is part of my work at Synapse.  
13 At my direction, a background check was performed on Mr. Nobles. His past history indicated  
14 that he inflated his academic credentials. Our research indicated that during an earlier attempt to  
15 market a company on the Vancouver Stock Exchange, Mr. Nobles had claimed to have advanced  
16 academic degrees, including a degree from the University of Texas, and a doctorate in  
17 biomedical engineering from UCLA. During our investigation, we learned that it had been widely  
18 reported in trusted market investment journals that Mr. Nobles had been caught in a lie over  
19 these claims, and had been forced to admit that he possessed no degrees of any kind.

20 5. We confronted him over these issues, as we were quite concerned about the  
21 implications. Nobles admitted that he had claimed to have these degrees, and that he in fact did  
22 not have any degrees. However, he claimed that the whole thing was not his idea--that his then-  
23 business partners had put him up to it. We had concerns about this, of course, but the investment  
24 in Sutura, Inc., seemed quite solid, and at that time we took him at his word that the whole  
25 episode was the result of youthful indiscretions. We decided to proceed with the investments. It  
26 was a decision that we would soon learn to regret.

27 ///

28 ///

1           6.       By December, 1999, Synapse Fund I, LLC, and Synapse Fund II, LLC, had each  
2 invested \$5,000,000.00 in Sutura, Inc. Synapse Fund II, LLC, made a separate investment of  
3 \$1,000,000.00, for a total of \$11,000,000.00.

4           7.       I personally invested \$40,000.00 of my own money in the company; my brother,  
5 Leif, invested \$40,000.00 as well.

6           8.       The stated purpose of these investments was to help Sutura to develop and bring  
7 to market medical devices, or at least to develop them to the point where the company could  
8 attract further investors, or even—and this is often considered the Holy Grail in these matters—be  
9 sold to a major player in the field.

10          9.       From early 2000 until September of 2001, the relationship between Mr. Nobles  
11 and the investors was pleasant. However, after Sept 2001, and repeated problems with raising  
12 additional funding, the relationship turned acrimonious. We did not receive timely updates on  
13 Sutura’s progress, and the transactions that Mr. Nobles proposed sounded more and more  
14 desperate, as well as preposterous: gold-backed debentures, reverse mergers, and private equity  
15 investments from the Cayman Islands and the Turks and Caicos Islands. These are not methods  
16 by which legitimate companies raise funds.

17          10.      At this point, we began to dig further. We learned that Mr. Nobles had taken  
18 certain steps with the management of Sutura, Inc., which seemed to be a fraud on investors. The  
19 first was that we learned that Sutura, Inc., had made several personal loans to Mr. Nobles, which  
20 he had then directed Sutura, Inc., to forgive. He also had caused Sutura, Inc., to lend him money  
21 to personally purchase the building where Sutura is located, at 17080 Newhope Street, Fountain  
22 Valley, CA 92708, and to put that building into his own name. We objected to these  
23 transactions. They could not possibly be advantageous to a company desperately trying to raise  
24 further capital for R&D, and to make itself attractive to a buyer. Such practices would be pure  
25 poison to any potential investor.

26 ///

27 ///

28 ///

1           11.     After 2003, Sutura received funding through Whitebox Advisors, which published  
2 an investment letter, the *Whitebox Market Observer*. We had pointed out to Whitebox the  
3 problem with Mr. Nobles's propensity for fraudulently inventing academic credentials, as well as  
4 other mismanagement by Mr Nobles and his partner, Mr. Egbert Ratering (as discussed in the  
5 paragraph below). Attached as **Exhibit A** is the *Whitebox Market Observer* of January, 2005,  
6 which sets forth the findings concerning Mr. Nobles's academic fraud. Nonetheless, Whitebox  
7 decided to proceed with its own investment.

8           12.     In June, 2005, I joined, together with the Synapse Funds in a lawsuit against Mr.  
9 Nobles and Mr. Egbert Ratering to stop the transaction proposed by Nobles and Ratering for  
10 Sutura. This was to be a reverse merger with a company called Technology Visions. The  
11 transaction would have been a disaster for Sutura, and for previous investors, as our position  
12 would have been significantly diluted. Attached as **Exhibit B** is a true and correct copy of the  
13 lawsuit that we filed against Nobles and Ratering and Sutura, in the Orange County Superior  
14 Court, Case No. 05CC00137. The insanity of the merger, the havoc that it would wreak on  
15 Sutura, Inc., and its investors, is all described in Paragraphs 6-10, at p.2, 1.24-p.3, 1.23.


16           13.     That case was settled in May, 2007.

17           14.     Our investment in Sutura, Inc., has been a complete loss. The Synapse funds lost  
18 their entire investment of \$11,000,000.00; I and my brother Leif lost every penny of each of our  
19 \$40,000.00 investments.

20           15.     During the time that I was involved with Sutura Inc., and Anthony Nobles, I  
21 visited him at his home at 8686 Tern Avenue, in Fountain Valley, California. I remember that he  
22 told me that he had personally done all of the wiring in the house; he also claimed that he was a  
23 workaholic, and got by on less than four hours sleep per night.

24           I declare under penalty of perjury under the laws of the State of California that the  
25 foregoing is true and correct.

26           Executed on January 28, 2014, at Torrance, California.

27  
28   
Leon Chiu

**EXHIBIT A**



# The Cult of Equities

W

hy are private accounts for Social Security a far more realistic and popular idea today than they were even in 2000 at the height of the boom?

Ronald Reagan first proposed partly privatizing Social Security in 1976. President Ford ridiculed the idea; no one really could be gotten to take it seriously.

This might have been because the country was coming off a couple-decade stretch wherein putting one's money into common stocks seemed to have been a manifestly bad idea (though the payoff was just around the corner). Four years later Reagan was elected and the great boom began. Even then private Social Security accounts did not become a serious political idea.

Bill Clinton was one of the most fiscally conservative presidents of the twentieth century, artfully letting a Republican Congress shove him into the briar patch of budgetary restraint and even reforming welfare. He was in a better position to straighten out Social Security than any Republican. Yet even at the top of the greatest bull market in history, private accounts were not seriously on the radar screen.

Now they are. Our guess is that they are at least even money to happen in some form. On the whole, we are glad, but the current framing of the issue seems to us to obscure the two things that are really happening.

The first is that Social Security as we have known it isn't being reformed—it is being abolished—or rather the cover for its inevitable demise is being established. It

is being allowed to die because it was created as a welfare program for poor people and is completely unsuited to serve as a pension program for the middle class, its current purpose.

## INSIDE

TWR, SUTURA, ASSET ALLOCATION,  
STEEL, REITS, PHARMA & OIL



The wise men of the *WSJ* argue that funding the transition to private accounts with a few hundred billion or even the odd trillion in government debt will not so much increase the net obligations of the U.S. government as begin to put trillions of unfunded obligations on the books. That's true if one considers projected S.S. benefits as actual obligations of the government, as the *Journal* urges us to. But a political promise is not a full faith and credit obligation; welfare programs are not pensions; Congressman cannot be sent to jail for renegeing on promises or changing policies. All the fretting about the consequences of Social Security "going broke" as if there were anything there to go broke is plain nonsense.

**Capital is not much use without something useful to invest in.**

Promises and schedule of benefits that were once useful are not anymore. Inevitably either benefits will be too niggardly for future middle class retirees or costs will be too high for middle class taxpayers. It's better to accept that Social Security is obsolete rather than spend trillions more fending off a mythical "bankruptcy"

that would have none of the consequences of the real world version. The best argument for private accounts is that as they grow in size and consequence they will gradually render tolerable the inevitable winding down of the old program until it dies or is rendered de minimis.

Nevertheless—and here is the other important issue that's not quite being grappled with—private mandated Social Security accounts are not free market capitalism. The largely un-remarked core of this entire notion is that for all practical purposes U.S. citizens will have been placed under a legal obligation to invest in the stock market. And at least for the transition period that investment will be financed by the U.S. government. Effectively U.S. taxpayers will be making an obligatory leveraged investment in equities with the government as guarantor.

The result, all other things being equal, is that prices will rise from already frothy, not to say bubbly levels, and earnings yields (the S&P last week was returning a pathetic 4.87 percent) will decline even further. Or to look at it from another direction, U.S. corporations will have even cheaper access to capital.

Is this a good thing?



THE WHITEBOX MARKET OBSERVER

Editors: ANDREW J. REDLEAF & RICHARD VIGILANTE  
Art Director: CHARLES BORK • Managing Editor: MARIE LAVINIO

*The Whitebox Market Observer* is published monthly by Whitebox Strategies, LLC. The authors, their families, and their clients, officers, employees, members, partners, or affiliates typically have long or short positions (or options or warrants relating to such positions) in any of the securities or sectors discussed in this or other published reports, and may purchase and sell these securities, options, or warrants from time to time in the open market or otherwise.

Views and opinions expressed as of the date of publication are exclusively those of the individual authors and are subject to change based on market and other conditions. This publication is provided for informational purposes only and should not be used or construed as a recommendation for any security or sector. Readers are responsible for conducting their own independent research before making a decision to invest in the sectors or securities profiled. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor prior to any such purchase or sale.

Neither the authors nor Whitebox Strategies, LLC can be held responsible for any direct or incidental loss incurred by applying any of the information in this publication. Although information in this publication is carefully verified, data are not guaranteed as to accuracy or completeness. Past performance of securities or sectors does not guarantee the future success of such securities or sectors.

A 12-month subscription to *The Whitebox Market Observer* service is available for \$450. Discounts can be obtained by subscribing online at [www.whiteboxstrategies.com](http://www.whiteboxstrategies.com). Subscription inquiries and address changes should be sent to *The Whitebox Market Observer*, 3033 Excelsior Boulevard, Suite 300, Minneapolis, MN 55416. Tel: 612-253-6030; fax: 612-253-6031.

© 2005 Whitebox Strategies, LLC. All rights reserved. Reproduction without permission is expressly prohibited.

Broadly speaking, a society that saves more and invests more will get richer over time. But this process is far from smooth. Capital is not much use without something useful to invest in. A very substantial minority of U.S. corporations burn more wealth than they create every year. Absent some pent-up demand of good projects going unfunded a sudden and arbitrary infusion of new capital would simply fluff up prices. As workers operating more or less under compulsion buy in, who will cash out? Not the money managers and institutions that are professionally committed to equities. Corporate insiders are far more likely candidates. In effect, by a combination of subsidy and compulsion, the government will be shifting share ownership from the knowledgeable to the uninformed, from the canny to the gullible. Joe Paycheck will be forced by his government to buy out Johnny Capital Gains at Johnny's price.

So why isn't Joe Paycheck objecting?

There can be only one answer. Five years after March 2000, the cult of equities lives.

The cult of equities lives today because the Fed (to its credit, given the choices) engineered about as soft a landing from the crash as one could have possibly imagined. As Churchill noted, the experience of being shot at without effect is wonderfully exhilarating. It's especially fun if the bullet-proof vest is woven from hastily printed dollars. Perhaps that explains bullish sentiments sitting at an all time high less than five years after the second-worst cataclysm in stock market history. It took five decades after 1929 for Joe Paycheck to get back into the market in a big way. This time it took about five months.

Positive feedback loops are the essence of business cycles. The cult of equity was preserved by the Fed virtually forcing money back at stocks. The resurgence of the cult is now making

Social Security private accounts a realistic possibility, which would tend to divorce prices even further from the reality of returns. And though a private accounts program would at first have little direct impact on demand for equities, prices may well get up and run simply on passage of the plan in anticipation of future demand.

It was far easier to find underpriced stocks even in 1999 and 2000 than it is today. If that sounds surprising, recall that the bubble, like most, was a bubble in a particular sector: tech and Internet stocks. Much of the money flowing in to new economy stocks was flowing out of old economy stocks, creating some excellent bargains. That's not the case today. Though large caps have lagged for the last several years, overpricing is spread far more evenly throughout the market now than five years ago. We face not a bubble but a blob.


But bubbles or blobs, they all deflate eventually. One scenario we can imagine is that a private accounts bill passes, prices run on the news, and then the reality of net inflows disappoints, prompting a collapse. However it happens, if it happens one wants to be in on the kill. Meantime, the market as a whole is not so tempting to make us want to let go of cash that could be a lot more useful sometime in the next year or so.

Our current proposed asset allocation includes

25 percent to the most lucrative cash equivalents practical. This seems more than ever like a good idea to us. In the nearly three years we have been publishing this letter, it was possible to record gains of several hundred percent cycling through stocks we have covered, but the vast majority of those gains would have come inside about 14

**We face not a bubble but a blob.**

WMO Apartment REIT Index





months from October 2002 to roughly the end of 2003. That, not the mythical 9 percent average annual return over 100 years, is the reality of the market. There is almost nothing more important to do than to preserve cash to have around when bargain day arrives.

As to the rest of our allocations, neither the sectors nor our world view are much changed. We still think the future contains more inflation than the immediate past, or rather that we will see continued evidence of the inflation that has already occurred. Despite modest official inflation figures, the signs of too much money are everywhere. The gold, commodity, and currency stories are too well known to recite here. But wasn't it interesting that one of the bits of news that helped drive oil back down from the orbital 50s to the merely stratospheric 40s was the revelation of unexpectedly high inventories? It's not just oil. One keeps running into high inventory anecdotes, all a little surprising given the several-decades-long trend the other way, of "just in time" inventory management only recently intensified by the inventory dread of the post-bubble contraction. The *WSJ* finally did a story on it the other day, noting that in an environment in which money costs less than anticipated commodity price rises, it pays to stockpile.

We still see an outside chance of that inflation becoming severe, especially due to political instability. (Staunch conservatives though we are, the Republican Party is the most overbought stock in the market right now.)

Big Pharma is still remarkable for being an underpriced sector in an overpriced market and still has more long-term appeal than almost anything we can think of. It certainly deserves 7 percent of our assets if not more. Lilly has come down from the nosebleed territory it habitually occupies. We were tempt-

ed to add it to our basket, rounding out the six companies we want in there. We decided to wait and see if it doesn't become really cheap as opposed to just cheap for Lilly. Our 7 percent each in oil and steel are supported by inflation with an upside in China.

We have 20 percent in apartment house REITs which were up so much that we were just considering selling some off when they sold themselves off. We think they are fine for now and we like the dividend yields at our purchase price. If they pop again we might sell some off and increase our allocation to near cash.

The one blank left in our program is our proposed 7 percent allocation to financials. Why financials? A better phrasing is "why not financials?" Compared to the market, we are severely underweighting the sector. Something like 20 percent of the S&P market cap is in financials; we are proposing 7 percent. We are not enthusiastic about the sector, in part because of inflation fears and in part because of our devotion to Stein's law: "If something can't go on forever it will eventually stop." We have gone through two decades of watching the financial industry create new forms of liquidity to purvey. It's hard to think of what could be next and it's even harder to make the case that the demand for liquidity can continue to grow at the remarkable pace of the last twenty years. Computers have already been invented once; derivative markets have already been created once; everything that isn't nailed down and quite a few things that are have already been securitized. Inflation is a condition in which the supply of liquidity exceeds the demand for it—bad news for liquidity providers.

We are doing our modest 7 percent mostly as, well, a gesture toward modesty, a hedge against the possibility that one of our biggest ideas, that the era of the financier is coming to a close, might be wrong and that we are imagining this inflation thing.

Moreover, in an overvalued market financials do look a bit cheap, at least on the surface. On the other hand, they almost always do, at least on the surface. Scan through the PEs of perfectly respectable banks and insurance companies, including quite a few large ones, many with all the marks of true quality including long



records of smooth and rising earnings and rich ROE, and you will probably be struck by the positively anemic PEs especially in this fat market. Bank of America can be had for a PE of around 12. Allstate also rates only a 12 with a forward of 9. Everest RE, a decent sized re-insurer trading near its all time high, scores a PE of less than 12. We could list dozens more. Nor are these numbers unusual. On an earnings basis these companies are almost always cheap compared to the market.

Most financials are black boxes bearing unknown and essentially unknowable credit, interest rate, and asset quality risk. All an investor really has to go on is track record and even that is dicey: the records are created by people who understand money too well for their investors' good and who hail from an industry that was fanatically image conscious even back when few financial institutions were publicly traded companies. The cloud of unknowing imposes a permanent discount on these prices. On the other hand, with the rest of the market so fat, the current earnings yield on these companies is at least some compensation for owning them.

If we have to do financials, however, we prefer to do them our way, which is to overweight insurance companies. Insurance is an inherently better business than modern banking. Customers are less demanding and often act out of financially irrational motives. Barriers to entry are not huge but they are much better than for banks, thanks to the meddlings of fifty state insurance regulators.

There are lots of non-bank banks competing with Citi and BoA—non-insurance company insurers are a much rarer breed.

Also we think the near future will be kinder to insurance companies than to banks. Logically as interest rates and thus investment income rises, insurance premiums should fall. But

while the rise in investment income should be swift and nearly automatic, premiums tend to be fairly sticky. For a while at least rising rates should favor insurers.

So who to buy? Remember these companies are black boxes. You really can't know what you are getting.

So we suggest acting on a few rebuttable presumptions. Book value is a useful metric for financials. Unlike say manufacturing or technology companies, which tend to be worth either a lot more or a lot less than their tangible assets, financial companies basically are their tangible assets, plus brand. In the absence of outright fraud, buying near or even under book value provides a margin of error. This is often possible with insurance companies; banks tend to sell for a lot more than book, in part because their liabilities tend to be overstated and in part because they are fee-making service companies. And it is reasonable to assume that big old companies with long good records are more stable than small new ones with short uninformative records.


What we think makes sense is to put maybe half of that 7 percent into individually selected insurance companies, looking particularly for big, long-lived firms that for some reason or other are currently selling near or even below book. That will usually mean they have had

some recent trouble: hurricanes, regulators, mergers the market dislikes. If the discount seems disproportionate to the trouble, they may be bargains. Two such at the moment are the newly merged St. Paul Travelers and AIG.

STA is cheap for three reasons. The best is that share prices throughout the sector got smacked by Florida: catastrophic losses

**Remember  
these companies  
are black boxes.  
You really can't  
know what you  
are getting.**

WMO Steel Index





### GET THE WMO FREE!

But not for nothing ...

We need more readers so we can get off hobby status and put this baby in the black. But unlike most newsletter writers we are subject to the amazing SEC restrictions on marketing that effectively preclude from the usual sort of solicitation.

But you can recruit as many new readers as you want, as enthusiastically as you like. And for everyone you bring onboard, we will extend your subscription for four months for free. Get us three subscribers a year and you'll never have to pay again!

How does it work? Like most things around here, pretty informally. Just send prospects to our website. Then if they sign up, e-mail us to say you sent them. We'll check it out and credit your account appropriately. Of course it doesn't count if they cancel within the first four months. In a few weeks we will add a "referred by" box to the website that will make it even easier. For now the e-mail to use is [info@whiteboxstrategies.com](mailto:info@whiteboxstrategies.com).

are almost always a buy signal in this sector. (We've sometimes been tempted to see if we could make a living just by buying insurance companies in hurricane season.) More specific to STA are some well-publicized post-merger glitches that may actually have cost the company business in the commercial lines. Once again, that's the kind of problem we usually like: depressing the share price in the near term but eminently fixable. The third and potentially most serious is the possibility that the company is under-reserved on asbestos, and, less seriously, on its surety policies for contractors that helped make such a mess of the Big Dig in Boston. Even here, though, there is a potential upside. The company made very large additions to reserves as part of the merger at least somewhat ameliorating the issue. It looks reasonably likely that there will be some political help on the asbestos front. Finally, though these reserve issues are large enough to be a real hit on earnings in a given year, none are worse than that. As we write St. Paul is at about 115 percent of book value, compared to about 145 percent for the sector, more than compensating for any necessary additions to reserves.

AIG is no longer being given away for free as it was immediately after the bid-rigging scandal broke. That would really have been the time to buy. But with a trailing PE of below 16 and a forward of below 13, \$67 is still a nice price to pay for a company with a long and lovely earnings and growth record, an ROE in the low teens, merely collateral exposure to said scandal, and a rare potential for multiple rebound

given the company's growth history and prospects.

And don't forget PTA. We are covering it as a special situation, but it fits nicely here too. It is not large or old, but having been recently subjected to serial colonoscopies from dozens of state regulators, it isn't a black box either. It is still selling at a huge discount to fully diluted book, and we love the growth prospects of its business line: long-term care insurance.

What else? We are going to look at small and regional banks in a future issue. But remember this is the black-box sector. Knowledge justifies concentration; ignorance demands diversification. If half our 7 percent is going into these three insurers, there is a decent argument to just stick the rest into a fully diversified financial sector ETF. (You can tell how much we love this sector, huh?)

### THE SUTURA SHAMBLES

No, we don't mean that. The product is terrific. The growth prospects stupendous. We love it. But the reverse merger process is a little messy as promised. And then there is the CEO, Tony Nobles. We are confident he is for real as a medical device guy and even an entrepreneur. But he is not, well, but-toned-down. Ask Tony what two plus two equals, and he'll tell you "Four!!!!" and sound like he is hyping the results while telling the Gospel truth. On the other hand everything he has said to us so far has been true, especially about Superstitch, the Sutura device for

suturing arteries opened even several inches below the skin for procedures such as placing a stent.

Still imagine our chagrin a couple weeks ago when a reader brought to our attention the following passage in a book by short-seller Manuel Asensio:

Harry Moll passed control of Turbodyne to his longtime associate Logan Anderson, who in turn passed control to Leon Nowek. Nowek had been associated with Moll in Northfolk Ventures Ltd., which ran into regulatory trouble in 1992 after its founder, Dr. Anthony Nobles, was found to have falsified his academic credentials.

As we observed on our blog at [www.whiteboxstrategies.com](http://www.whiteboxstrategies.com) the most unsettling thing about this was not that Nobles as a much younger man at some point hyped his credentials—he is enormously accomplished anyway with for instance more than twenty U.S. patents to his name and more to come—but that he was in some way tied into Harry Moll, an infamous promoter working out of the just as infamous Vancouver stock exchange. We asked Nobles for an explanation and we got it in the form of a letter his lawyers send out when the subject comes up. Within the obvious limits it is a pretty good letter. Yes, Nobles did inflate his academic credentials, and, yes, the promoters used that information in a disreputable and manipulative way. But Nobles did not know what they were doing with the information, had no clue they were scoundrels, and at that point being completely

naïve on the financial side had no clue the Vancouver exchange was a hangout for scoundrels. In any event Nobles paid the price: he was forced out of companies he created by the same crew of scoundrels that once hyped his qualifications to investors.


Besides the fact that this letter comes from a large and, as law firms go, respectable source (so we damn with faint praise), Baker and McKenzie, and the fact that the explanation has long satisfied Goldman Sachs and other backers, it rings true to us. We can just imagine the young Tony Nobles, smart as a whip, an inventor/entrepreneur, who sets himself outside the establishment because he thinks he is smart enough to do without it, but who finds out repeatedly that what the world really wants is those paper credentials he never bothered with. He's just as smart or smarter than those guys. He's done what they have done and more. He has what those letters mean. So what the heck? They are just letters.

If it were just our own money, this would be a non-issue. We don't really care about the 1992 incident; it hasn't affected our own intentions on Sutura. We're writing about it here because we introduced our readers to this company and to Tony Nobles and we want you to know what we know and make your own decisions.

On the merger. Our reference to "mess" above does not mean we think the merger is not happening. It seems quite likely to happen. The mess was the lack of clarity from all parties on the exact diluted share count for TVGR, from which one figures the implicit post-

**Knowledge justifies concentration; ignorance demands diversification.**

WMO Big Pharma Index






merger market cap looking at TVGR's share price today. The short answer is that TVGR's final share count will be 141.1 million (which will be shrunk at the time of closing via a one for twelve reverse split). Since TVGR will get 5 percent of the final company, you can figure the implied market cap from there. At the time we first wrote, with TVGR, at 7 cents the implied market cap was \$200 million, almost double what we believed at the time. Today it is somewhat higher.

So is it a good deal? Maybe. If this company works it will certainly be worth several times its current implied value. But patience is such a good thing. Everything gets cheap from time to time and start-ups especially. New sales force. New production facilities. Volume ramp-up. What are the odds that these guys will never have a bad news quarter or even that Mr. Market will never freak out on the downside for no reason at all? IFLO was selling for less than \$10 last July.

**What are the odds that Mr. Market will never freak out on the downside for no reason at all?**

Plus there is this big problem with TVGR. Pennies. Nobody can count in pennies. Stock jumps from 7 cents to 11; what the heck—that's only 4 cents—it's still free. Right. It's a 57 percent move. Although the cliché is that penny stocks gain value from reverse splits that make them seem more real, and though logic suggests

### WMO Oil Index



that the price should rise once the merger is actually done, it makes just as much sense to us that the price will drop once buyers are counting in dollars and fretting over reality rather than fantasizing over prospects.

### TWR'S DEAL

**B**riefly on TWR: as noted on our website the company did get approval on that first \$50 million tranche of the AR securitization program it is seeking, with net proceeds of \$44 million. That substantially improves their liquidity. There is potential to expand this to \$200 million, pending ongoing negotiations with the same creditors who eventually agreed to allow Tower to close on the \$50. In addition TWR is negotiating for a \$30 million AR facility in Europe, permitted under its existing credit agreements.

The \$44 million considerably improves the company's position; they probably don't need the rest of the money—unless more bad things happen. We stand by our view which is that if TWR made it into the New Year the company would survive. The quarterly conference call could be huge. If there has been no more bad news we would expect the share price to begin recovering fairly quickly. If the quarter's news is ambiguous then we will probably have to wait for another catalyst.

*—Andrew J. Redleaf and Richard Vigilante*

*January 14, 2005*

### Special Opportunities

As you know we have abolished our old WMO Model Portfolio because our lawyers hated it. But uncovering and staying on top of unusually promising stocks is still our major focus. Currently we are actively covering all the stocks that were in the portfolio as of last issue, except for the shorts. We will continue to update them just as if the portfolio were still active. For a reminder the current list includes ACP, ALDA, BSET, BWNG, DRRA, IFLO, PCL, PTA, SMF, SPAN, TALK, TOX, TWR.

# **EXHIBIT B**

1 SAMUELS GREEN STEEL & ADAMS, LLP  
2 Mark S. Adams, Esq. SBN 125485  
3 Eoin L. Kreditor, Esq. SBN 151131  
4 Monica Q. Vu, Esq. SBN 216352  
5 19800 MacArthur Blvd., Suite 1000  
6 Irvine, California 92612  
7 Telephone No. (949) 263-0004  
8 Facsimile No. (949) 263-0005

9 Attorneys for All Plaintiffs

10 SUPERIOR COURT OF THE STATE OF CALIFORNIA  
11 COUNTY OF ORANGE - CENTRAL JUSTICE CENTER

12 GO INDUSTRIES, INC., a Florida  
13 corporation; SYNAPSE FUND I, LLC, a  
14 California limited liability company;  
15 SYNAPSE FUND II, LLC, a California  
16 limited liability company; KENNETH A.  
17 BARNETT; MARION BATES; PHILIP V.  
18 and KATE HUTCHINS BATES, JTWROS;  
19 BELINFER CORPORATION; LEON A.  
20 CHIU; COLUNGA LIVING TRUST; JACK  
21 GREGORY; DANIEL G. HALL; RUDY  
22 KRANYS; SHERRY KRANYS; PHILIP J.  
23 and SUSAN MONKS, JTWROS; IRWIN D.  
24 NOVAK; JESSICA K. NOVAK; JUDI M.  
25 NOVAK; RYAN T. POWELL; TAYLOR B.  
26 POWELL; MARTIN TERRY ROTHMAN;  
27 BRUCE E. and NANCY STIMSON, WMS,  
28 JTWROS; GARY BECKER; ROBERT C.  
STRAUSS GRANTOR RETAINED  
INTEREST TRUST; RENA WHITE  
CONNER; and MARK H. WHOLEY  
FAMILY LTD. PARTNERSHIP;

Plaintiffs,

v.

ANTHONY A. NOBLES, EGBERT  
RATERING, and SUTURA, INC., a Delaware  
corporation,

Defendants.

**FILED**  
SUPERIOR COURT OF CALIFORNIA  
COUNTY OF ORANGE  
CENTRAL JUSTICE CENTER

JUN 30 2005

ALAN SLATER, Clerk of the Court

BY E. BLOMBERG DEPUTY

Case No.:

**05 CC00137**

**JUDGE JONATHAN H. CANNON**

**DEPT. CX102**

**COMPLAINT FOR INVOLUNTARY  
DISSOLUTION; REMOVAL OF  
DIRECTORS; AND INJUNCTIVE  
RELIEF**

Exhibit B Page 1 of 9

1 Plaintiffs, by and through their attorneys of record, allege for their Complaint as follows:

2 **COMPLAINT**

3 1. Defendant Sutura, Inc. ("Sutura") is a privately-held Delaware corporation, with its  
4 principal place of business in Fountain Valley, California. Plaintiffs allege on information and  
5 belief that all of Sutura's assets, books and records are in California, all of its business has been  
6 conducted here, and Sutura has no directors or officers in Delaware. Sutura is engaged in the  
7 business of developing, manufacturing and marketing medical devices, including SuperStitch<sup>®</sup>,  
8 a suturing device used in vascular surgery.

9 2. At all times herein mentioned, and at the time of the conduct and actions complained  
10 of herein, Plaintiffs were, and still are, the record and/or beneficial stockholders of Sutura. In  
11 the aggregate, Plaintiffs own approximately 30 % of Sutura's outstanding common stock.  
12 Exclusive of the shares owned by Defendants Anthony Nobles and Egbert Ratering and their  
13 affiliates, Plaintiffs' total ownership interest in Sutura is 74%.

14 3. Defendant Anthony Nobles ("Defendant Nobles") is and at all times herein  
15 mentioned was an individual residing in Orange County, California. Since at least July 1998, he  
16 has been Sutura's Chief Executive Officer, except for a period of time between January 2000  
17 and March 2002 during which he served as Sutura's Chief Technology Officer. Also since at  
18 least July 1998, Defendant Nobles has served as a member of Sutura's Board of Directors.

19 4. Defendant Egbert Ratering ("Defendant Ratering") is and since at least July 1998 has  
20 been, Sutura's Executive Vice President and Director of European Operations. Also since at  
21 least July 1998, Defendant Ratering has served as a member of Sutura's Board of Directors.

22 5. Defendants Nobles and Ratering, through their company Grootkasteel B.V., and  
23 through other affiliates, beneficially own 54.62% of Sutura's outstanding common stock.

24 6. Defendants Nobles' and Egberts' management of Sutura is on a path to destroy the  
25 company. Of recent and primary importance is Defendants' plan to merge Sutura with  
26 Technology Visions Group, Inc. ("TVG"), a Delaware corporation, through a stock-for-stock  
27 transaction, after which Sutura stockholders would hold 95% of the combined entity's common  
28 shares (the "TVG Transaction"). TVG, however, is little more than a shell company with an

Exhibit B Page 2 of 9

1 OTC listing on the so-called "Bulletin Boards," liabilities that far outstrip its assets, consistent  
2 losses and negative cash flow.

3 7. The most recent year-end audited financial statements disseminated in the proxy  
4 statement issued with respect to the TVG Transaction disclose that, as of December 31, 2004,  
5 TVG had assets of \$134,838, liabilities of \$1,987,085, combined losses since inception of  
6 \$18,829,426, and total stockholders' deficit of negative \$1,852,247. There were no revenues in  
7 2004, and the company suffered a net loss of \$758,205. The Auditors' Opinion notes that  
8 TVG's financial condition "raise substantial doubt about the Company's ability to continue as a  
9 going concern." Since January 1, 2002, TVG's stock has traded in a range from a high of \$0.20  
10 a share (in mid 2003) to a low of \$0.03 a share, and even now, after several announcements of  
11 its merger with Sutura, is trading in the range of \$0.04 to \$0.06 during the month of May 2005.

12 8. TVG's incentive to pursue the TVG Transaction is easily discerned. The  
13 Information Statement describes the company as suffering "increasingly severe financial  
14 distress" and expresses the hope that the transaction will provide TVG with "increased  
15 opportunities for new funding."

16 9. In contrast, Sutura will not gain any benefit from the TVG Transaction but will be  
17 severely injured financially if it is consummated.

18 10. As of today, Sutura is a financially troubled company. Its most recently publicly-  
19 available financial statement, for the year ended December 31, 2004, notes certain "factors" that  
20 "raise substantial doubt about the Company's ability to continue as a going concern." The TVG  
21 Transaction can only make Sutura more unstable. Unless the TVG Transaction is enjoined,  
22 Sutura will be saddled with a money-losing operation that will exacerbate its own serious  
23 financial problems and will further erode its ability to invest in the promise of its own products.

24 11. Absent an injunction, any prospect for the minority stockholders, including  
25 Plaintiffs, to recoup the value of their investment will eventually disappear. Plaintiffs have no  
26 adequate remedy at law.

27 ///

28 ///

Exhibit B Page 3 of 9



**FIRST CAUSE OF ACTION**  
**(For Involuntary Dissolution)**

12. Plaintiffs reallege and incorporate by reference the allegations contained in paragraphs 1 through 11 inclusive, as though fully set forth herein.

13. Plaintiffs are the holder of about three-fourths of the outstanding common shares of Sutura, excluding shares owned by persons who have personally participated in transactions enumerated in California Corporations Code Section 1800(b)(4), and are entitled to maintain an action for involuntary dissolution thereof pursuant to California Corporations Code Section 1800.

14. Grounds exist for involuntary dissolution of Sutura pursuant to Corporations Code Section 1800 (b)(4), to wit:

(a) Defendants have demonstrated a pattern of self-dealing, including but not limited to, drawing excessive salaries, licensing Sutura's technology to other companies owned and controlled by Defendants for inadequate consideration, using Sutura's employees and resources to benefit Defendants' other, separately owned companies without reasonably compensating Sutura for same, improperly causing Sutura to forgive Defendant Nobles' and his spouse's loan from the company, improper payment by Sutura to other companies from which Nobles will receive improper benefit, and using Sutura's funds to pay for personal expenses;

(b) Defendants have mismanaged and abused their authority in operating Sutura by, among other things, negotiating and intending to enter into financing transactions that will serve no conceivable benefit to Sutura but will only leave the company a mere shell with excessive liabilities and that will dilute the ownership interest of existing invested shareholders without a corresponding benefit to the Company;

(c) Defendants have committed acts constituting waste of Sutura's assets, including but not limited to, failing to market and capitalize on Sutura's technologies, such as the SuperStitch ® device, to the detriment of Plaintiffs and Sutura's other shareholders;

///

///

Exhibit B Page 4 of 9

1 (d) Defendants have made and continue to make fraudulent and misleading  
2 statements to potential investors regarding, among other things, Sutura's financial status and  
3 products, which fraud subjects Sutura to potential and massive lawsuits;

4 (e) Defendants have persistently treated the minority shareholders with unfairness by  
5 among other things, conspiring to buy out other shareholders at below market price and refusing  
6 to inform the shareholders of Sutura's financial status and condition; and

7 (f) In September 2002, Defendants Nobles and Ratering engineered the removal of  
8 an independent director, Alfred Novak, from Sutura's Board of Directors, unwilling to accept  
9 Novak's growing skepticism about their activities. Novak's removal was timed to permit  
10 Defendants to approve transactions that would have benefited them personally to the detriment  
11 of the Company.

12 15. Plaintiffs further allege that dissolution of Sutura is necessary for the protection of  
13 Plaintiffs' rights and/or interests as shareholder of Sutura and to eliminate the risk of growing  
14 liabilities, including liabilities created by the misconduct of Defendants Nobles and Ratering.  
15 Moreover, a receiver is required to supervise the dissolution in order to preserve the value of  
16 Sutura's assets.

## 17 SECOND CAUSE OF ACTION

### 18 **(Removal of Defendants Nobles and Ratering as Directors of Sutura)**

19 16. Plaintiffs reallege and incorporate by reference the allegations contained in  
20 paragraphs 1 through 15 inclusive, as though fully set forth herein.

21 17. Plaintiffs are the holder of record of more than ten percent of the outstanding  
22 common shares of Sutura, and are entitled to maintain an action for removal of directors thereof  
23 pursuant to California Corporations Code Section 304.

24 18. Defendants Nobles and Ratering are, and at all times herein mentioned were,  
25 directors of Sutura.

26 19. Defendants have committed fraudulent and dishonest acts in managing Sutura and  
27 have grossly abused their authority as directors of Sutura by, among things:

28 (a) drawing excessive salaries;

Exhibit B Page 5 of 9

- 1 (b) licensing Sutura's technology to other companies owned and controlled by  
2 Defendants for inadequate consideration;
- 3 (c) using Sutura's employees and resources to benefit Defendants' other companies  
4 without reasonably compensating Sutura;
- 5 (d) improperly causing Sutura to forgive Defendants' loans from the company;
- 6 (e) making payments from Sutura to entities from which one or both Defendants  
7 would derive personal benefit, without the company deriving commensurate benefit;
- 8 (f) using Sutura's funds to pay for personal expenses;
- 9 (g) negotiating and intending to enter into financing transactions that will serve no  
10 conceivable benefit to Sutura but will instead leave the company with excessive liabilities and  
11 dilute the ownership interest of investor shareholders without corresponding benefit to the  
12 company;
- 13 (h) making fraudulent and misleading statements to potential investors regarding,  
14 among other things, Sutura's financial status and products, which fraud subjects Sutura to  
15 potential and massive lawsuits;
- 16 (i) conspiring to buy out other shareholders at below market price and refusing to  
17 inform the shareholders of Sutura's financial status and condition; and
- 18 (j) engineering the removal of an independent director, Alfred J. Novak, from  
19 Sutura's Board of Directors in September 2002, because Novak expressed skepticism and  
20 concern about their activities. Novak's removal was timed to permit Defendants to approve  
21 transactions that would have benefited them personally without corresponding benefit to the  
22 company.

23 20. As a result, removal of Defendants as directors of Sutura is necessary in order to  
24 protect Plaintiffs' rights and/or interests as shareholder of Sutura.

25 **THIRD CAUSE OF ACTION**

26 **(Injunctive Relief)**

27 21. Plaintiffs reallege and incorporate by reference the allegations contained in  
28 paragraphs 1 through 20 inclusive, as though fully set forth herein.

Exhibit B Page 6 of 9

1 22. Beginning since late 2004 and continuing to the present, Defendants Nobles and  
2 Ratering, and each of them, have planned and plotted to consummate the TVG Transaction even  
3 though such transaction will not benefit Sutura in any way, but will cause the company's  
4 financial destruction.

5 23. Despite numerous requests by Plaintiffs and other shareholders of Sutura to  
6 Defendants to find alternative, reasonable financing for Sutura, Defendants are intent on  
7 consummating the TVG Transaction, even if it means crippling the company.

8 24. The consummation of the TVG Transaction, unless and until enjoined and restrained  
9 by order of this court, will cause great and irreparable injury to Plaintiffs as minority  
10 shareholders of Sutura because once the TVG Transaction is consummated, it cannot be  
11 unwound, and Plaintiffs' interest in Sutura will be destroyed forever.

12 25. Plaintiffs have no adequate remedy at law for the injuries that will be suffered if the  
13 TVG Transaction is consummated as it will be impossible for Plaintiffs to determine the precise  
14 amount of damage that they will suffer.

15  
16 **PRAYER**

17 **WHEREFORE,** Plaintiffs pray for judgment and relief as follows:

- 18 1. For an order dissolving Sutura and appointing a receiver to supervise its  
19 dissolution;
- 20 2. For removal of Defendants Nobles and Ratering from the office of director of the  
21 corporation;
- 22 3. For an order barring Defendants Nobles and Ratering from re-election to the  
23 office of director for a period of five years or such other period as the court prescribes;

24 ///

25 ///

26 ///

27 ///

28 ///

Exhibit B Page 7 of 9

1           4.     For order enjoining Sutura from taking any steps toward effectuation of the TVG  
2 Transaction or to consummate this transaction;

3           5.     For costs of suit incurred herein; and

4           6.     For such other and further relief as the Court deems just and proper.  
5

6 DATED: June 29, 2005

SAMUELS, GREEN, STEEL & ADAMS LLP

7  
8 By: 

Eoin L. Kreditor  
Attorneys for All Plaintiffs  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28


Exhibit B Page 8 of 9

1 VERIFICATION

2 I, Kenneth A. Barnett, am one of the plaintiffs in the above-captioned action. I have read  
3 the foregoing Complaint for Involuntary Dissolution, Removal of Directors, and Injunctive  
4 Relief and know the contents thereof. The same is true of my own knowledge, except as to those  
5 matters which are therein stated on information and belief, and as to those matters, I believe them  
6 to be true.

7 I declare under penalty of perjury under the laws of the State of California that the  
8 foregoing is true and correct.

9 Executed this 29<sup>th</sup> day of June, 2005, in Irvine, California.

10   
11 \_\_\_\_\_  
12 Kenneth A. Barnett